Feed - News and features

• MSD, Amgen back patient data specialist Culmination Bio
  The venture capital arms of MSD and...
• FDA starts review of Padcev/Keytruda for bladder cancer
  The FDA has kicked off a priority...
• AZ drops two trials aimed at expanding Lokelma’s label
  AstraZeneca has decided to abandon two...
• Cybin preps for ph3 as psychedelic clears depression trial
  Cybin has unveiled phase 2 results...

PharmaTimes: News RSS

• Prostate cancer focal therapy could improve costs and patient outcomes
• Radiotherapy boost shown to reduce treatment times for breast cancer patients
• SMART and CAMP collaborate to develop safer T-cell therapies
• School of Global Affairs and Ethox Centre launch new research hub
• Milner Therapeutics to establish new genomics laboratory for drug discovery

• Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023, PRAC, 01/12/2023
• Consumption of antimicrobials in animals reaches lowest level ever in Europe, , 20/11/2023
• Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 7-9 November 2023, CVMP, 10/11/2023
• Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023, CHMP, 10/11/2023

• Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression
• Local Sleep in Idiopathic Hypersomnia
• Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial
• OptimizeD Pilot Study